about
Current challenges in handling genetic data.Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons.Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsHealth economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UKCost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Influenza vaccination coverage rates in Europe--covering five consecutive seasons (2001-2006) in five countriesInfluenza vaccination: key facts for general practitioners in Europe-a synthesis by European experts based on national guidelines and best practices in the United Kingdom and the Netherlands.Increasing influenza vaccination coverage in recommended population groups in Europe.Personalized cancer medicine and the future of pathology.Herpes zoster vaccine: A health economic evaluation for Switzerland.Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons.Influenza vaccination uptake and socioeconomic determinants in 11 European countries.Developments in influenza vaccination coverage in England, Scotland and Wales covering five consecutive seasons from 2001 to 2006.Sozialer und ökonomischer Nutzen der Impfung gegen Influenza.Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.Trends in influenza vaccination coverage rates in Germany over six seasons from 2001/02 to 2006/07.Population access to new vaccines in European countries.The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.Economic burden of symptomatic iron deficiency - a survey among Swiss womenImpact of European vaccination policies on seasonal influenza vaccination coverage rates: An update seven years laterThe hypoxic transcriptome of the retina: identification of factors with potential neuroprotective activityCost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland
P50
Q30844057-5BEB4BA9-D7A7-482E-9D61-408BE21D1D40Q33357024-33E6AA7E-9125-49D3-A1BA-55A052930F4AQ34620222-647E423E-3B56-4C45-83C0-4AA4C4C13423Q35008290-2DB211A7-FD03-4B11-AE8E-14D6F4290785Q36050640-B02A29C5-5108-499B-8BA4-42A99069BA51Q36322947-80CB94B2-2E8B-4F3A-BBFC-A2F3E7AC88ECQ37087645-32708C4B-8EC5-48D0-AA74-3FBA13D4AFE2Q37152931-3BDA7A35-ABD9-426B-9CB0-35B6C93F7464Q37434523-603E4CFA-7F8D-4291-BDF0-FD377C227114Q37965048-344F4DF6-1E81-4B61-B9BA-A1F6B418EEDEQ38798312-ABAAB63B-37A3-4990-9783-A8F0A5BADDC4Q39945576-1AD1E110-704B-4FAE-80D5-8EDD96AA366BQ39985244-C99F0869-867C-4CD8-A38A-0B40EAA63735Q40163005-04F710EA-3DE3-4002-AC37-16C6BC4DDFF9Q40188512-A70554A5-EBA7-405C-8A07-390EE61FF837Q44308387-DB81E4DE-D069-46BE-8EFD-540024EAD9BDQ45802851-85CAE593-8D28-4A89-8405-EEC2C651F136Q48301850-73F381FF-9E5D-4CD1-807E-C26C1DAB6C1CQ50188721-78E3A2D1-95BA-42FF-9E65-A3229A36D9C9Q51083689-F90D24A0-E1C7-480A-B1AD-650A27A82994Q54570420-DB45A317-915A-4167-8951-F86CB6615591Q54683060-7B04AF2D-A695-476A-82D2-8667A1BFFB65Q64099437-3126DAE6-FE9D-4274-B20B-937081BEBEEFQ64137335-31CF3FE7-BBE2-4AA5-86C9-8B93241395C7Q80479753-B990EC51-865B-4A5E-9D27-4A872DBD386AQ83947722-AF59FA08-D2F4-4CF2-A0D3-5A75F60453C8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Patricia R Blank
@ast
Patricia R Blank
@en
Patricia R Blank
@es
Patricia R Blank
@nl
type
label
Patricia R Blank
@ast
Patricia R Blank
@en
Patricia R Blank
@es
Patricia R Blank
@nl
prefLabel
Patricia R Blank
@ast
Patricia R Blank
@en
Patricia R Blank
@es
Patricia R Blank
@nl
P108
P106
P1153
22937002300
P21
P31
P496
0000-0002-0180-3468